PubMed Health⌕ Search

Biomedical subjects

Marcos Eduardo Machado Paschoal

Publications and source records attributed to Marcos Eduardo Machado Paschoal.

4 recordsLinked to original sources
PubMed2006

Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report.

This study reports the reliability and validity of the Brazilian Portuguese version of QLQ-LC13. After translation and cross-cultural adaptation, the questionnaire was administered, together with the QLQ-C30 core questionnaire, to 82 patients with lung cancer. The analysis was based on 60 patients who completed two interviews, and who received chemotherapy alone or in combination with radiotherapy. The reliability or internal consistency of dyspnea scale was 0.79. The pain scale needed to be combined with the QLQ-C30 pain items to reach a satisfactory value of 0.73. The construct validity was supported by the ability of the questionnaire to discriminate patients regarding their performance status and type of treatment. However, the change over time, although in the expected direction for all items, was statistically significant in four of the 10 items studied. The criterion-related validity was supported by the statistically significant correlation between all four side effect items and the physicians' reports of toxicity, while the evolutive changes in the performance status were statistically significant in only four items. Most psychometric properties of the Brazilian version of the QLQ-LC13 were adequately supported in this analysis. However, a wider utilization of this module is necessary to fully ascertain its reliability and validity properties.

Adult↗
PubMed2005

Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients.

Based on the assumption that proteins can emanate from tumour to serum, we investigated whether serum low molecular weight proteins (LMW) can discriminate lung cancer patients from healthy donors. Pooled sera from 20 lung cancer patients matched in sex (men), histological type (adenocarcinoma) and stage (IIIB and IV) and from 20 healthy donors (men) were submitted to 2-DE coupled to MALDI-TOF peptide mass fingerprinting. Results of 2D-E/ MALDI-TOF showed five up regulated proteins (immunoglobulin lambda chain, transthyretin monomer, haptoglobin-alfa 2 and two isoforms of serum amyloid protein) and one down regulated (fragment of apolipoprotein A-I) in patients. All differentially expressed proteins, except immunoglobulin, may be acting as a non-specific sign of inflammation in cancer and transthyretin monomer may act as a possible blood marker to CSF barrier disruption that occurs, e.g., in cerebral metastasis. In conclusion, this work shows the usefulness of 2D-gel electrophoresis and mass spectrometry proteomic techniques for the identification of up- and down-regulated proteins in serum from adenocarcinoma lung cancer patients.

Adenocarcinoma↗
PubMed2004

Serum protein profiling of lung cancer patients.

Lung cancer is one of the leading causes of cancer deaths worldwide. The poor patients prognosis is largely attributable to the lack of effective early detection methods. Based on the concept that proteins and peptides can emanate from tumor to the serum, the present study aims to investigate if serum proteins pattern, assessed by a gradient polyacrylamide gel, is capable to discriminate 66 lung cancer patients from 44 healthy donors. Additionally, in a group of 10 patients and 10 healthy donors, it was also investigated by western-blot if apoptosis and metastasis-related proteins such as Bax, Bcl-2 and Hlm were present in serum. Our results showed that, in patients, protein bands of 180 kDa and 13 kDa were more frequent (Fisher, P<0.05) and a protein band of 124 kDa was more intense (Mann Whitney, P<0.05). In healthy donors a band of 158 kDa were more frequent (Fisher, P<0.05), a band of 24 kDa was more intense (Mann Whitney, P<0.05) and bands of 14 kDa and 9 kDa were together more frequent (Fisher, P<0.05) and intense (Mann Whitney, P<0.05). Bax, Bcl-2 and Hlm were not detected in serum. We conclude that changes in serum protein pattern of lung cancer patients can be detected by a simple methodology.

Adult↗